Oruka Therapeutics will report Week 16 data for ORKA-001 in psoriasis trial on April 27, 2026, followed by a conference call.
Quiver AI Summary
Oruka Therapeutics, Inc. announced that it will report Week 16 data for its investigational drug ORKA-001 from the EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis on April 27, 2026. Following the data release, the company will hold a conference call and webcast at 8:00 a.m. ET to discuss the findings, accessible via a link on their website. Oruka Therapeutics focuses on developing innovative biologics aimed at improving treatment outcomes for chronic skin diseases, with a mission to provide high rates of disease clearance for patients with conditions like plaque psoriasis, potentially requiring treatment as infrequently as once or twice a year. Their portfolio includes engineered antibodies that target crucial mechanisms associated with these diseases.
Potential Positives
- Oruka Therapeutics is set to announce clinical data for ORKA-001 from a significant Phase 2a trial, indicating advancement in their research and potential treatment options for chronic skin diseases.
- The webcast following the announcement allows for direct communication with investors, showcasing transparency and engagement with stakeholders.
- The company's focus on achieving high rates of complete disease clearance with infrequent dosing highlights its commitment to improving patient quality of life in treating chronic skin conditions.
- Oruka Therapeutics is developing a potentially best-in-class portfolio of antibodies targeting core mechanisms of plaque psoriasis, which could position the company as a leader in the biotechnology field for dermatologic diseases.
Potential Negatives
- The release does not provide any preliminary results or insights regarding the Week 16 data for ORKA-001, which may lead to uncertainty and speculation among investors and stakeholders about the treatment's effectiveness.
- The announcement of the upcoming webcast could imply that the company has significant data they feel is necessary to present live, which could be interpreted as a lack of confidence in the results being favorable if not presented preemptively.
FAQ
What is Oruka Therapeutics focused on?
Oruka Therapeutics focuses on developing novel biologics for the treatment of chronic skin diseases, especially plaque psoriasis.
When will Oruka report Week 16 data for ORKA-001?
Oruka will report Week 16 data for ORKA-001 on April 27, 2026.
How can I access the live webcast for the EVERLAST-A trial results?
The live webcast can be accessed via a link provided in the press release or on the Investors section of Oruka's website.
What is the goal of Oruka's treatments for chronic skin diseases?
Oruka aims to achieve high rates of complete disease clearance with infrequent dosing for patients with chronic skin diseases.
Who engineered the antibodies used by Oruka Therapeutics?
The antibodies developed by Oruka were engineered by Paragon Therapeutics to target mechanisms underlying plaque psoriasis and related diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ORKA Insider Trading Activity
$ORKA insiders have traded $ORKA stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $ORKA stock by insiders over the last 6 months:
- JOANA GONCALVES (Chief Medical Officer) has made 0 purchases and 15 sales selling 35,641 shares for an estimated $1,438,945.
- LAURA LEE SANDLER (Chief Operating Officer) has made 0 purchases and 6 sales selling 18,600 shares for an estimated $563,396.
- LAWRENCE OTTO KLEIN (Chief Executive Officer) sold 1,729 shares for an estimated $71,407
- ARJUN AGARWAL (Senior Vice President, Finance) sold 395 shares for an estimated $16,313
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$ORKA Hedge Fund Activity
We have seen 97 institutional investors add shares of $ORKA stock to their portfolio, and 28 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP added 1,710,316 shares (+inf%) to their portfolio in Q4 2025, for an estimated $51,839,677
- CABLE CAR CAPITAL, LP removed 1,600,000 shares (-80.0%) from their portfolio in Q4 2025, for an estimated $48,496,000
- BLACKROCK, INC. added 1,334,864 shares (+60.6%) to their portfolio in Q4 2025, for an estimated $40,459,727
- BRAIDWELL LP removed 1,297,555 shares (-93.9%) from their portfolio in Q4 2025, for an estimated $39,328,892
- STATE STREET CORP added 731,819 shares (+112.2%) to their portfolio in Q4 2025, for an estimated $22,181,433
- VANGUARD GROUP INC added 676,865 shares (+38.1%) to their portfolio in Q4 2025, for an estimated $20,515,778
- DEEP TRACK CAPITAL, LP removed 493,271 shares (-18.6%) from their portfolio in Q4 2025, for an estimated $14,951,044
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
$ORKA Analyst Ratings
Wall Street analysts have issued reports on $ORKA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/07/2026
- BTIG issued a "Buy" rating on 11/13/2025
- Jefferies issued a "Buy" rating on 11/13/2025
To track analyst ratings and price targets for $ORKA, check out Quiver Quantitative's $ORKA forecast page.
$ORKA Price Targets
Multiple analysts have issued price targets for $ORKA recently. We have seen 10 analysts offer price targets for $ORKA in the last 6 months, with a median target of $76.5.
Here are some recent targets:
- Martin Fan from Wedbush set a target price of $85.0 on 04/15/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $70.0 on 04/13/2026
- Yatin Suneja from Guggenheim set a target price of $125.0 on 04/13/2026
- Julian Harrison from BTIG set a target price of $78.0 on 04/13/2026
- Etzer Darout from Barclays set a target price of $78.0 on 04/07/2026
- Michael Yee from UBS set a target price of $75.0 on 04/06/2026
- David Risinger from Leerink Partners set a target price of $86.0 on 03/16/2026
Full Release
MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis on Monday, April 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.
Webcast Details
Oruka Therapeutics’ live webcast of the EVERLAST-A results will begin on Monday, April 27 th , at 8:00 a.m. ET. The live webcast can be accessed via this link , or through the Investors section on the company’s website at https://ir.orukatx.com/news-events/events-presentations . A replay of the webcast will be available following the call.
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
[email protected]
